Surgery Partners vs. Viemed Healthcare: Which Outpatient Care Stock Is a Better Buy in 2026?

The article argues Viemed Healthcare is the better 2026 portfolio pick, citing FY2025 revenue growth of about 21% to $270.3 million, net income of $14.9 million, and low debt-to-equity of nearly 0.1x. Surgery Partners posted FY2025 revenue of just over $3.3 billion, up about 6%, but remained unprofitable with a $77.9 million net loss and $3.7 billion in debt. The piece also highlights stronger expected 2026 revenue growth for Viemed (>17%) versus Surgery Partners (~3%), while noting regulatory and reimbursement risks for both companies.

Analysis

The market is still underestimating the divergence between asset-light care models and leveraged facility roll-ups. VMD’s mix shift toward home-based chronic care creates a cleaner reimbursement pass-through and a faster compounding path: when volumes rise, incremental margin should expand with relatively little balance-sheet drag, while SGRY’s growth still requires continuous capital deployment just to hold share in a regulated, fragmented market. That makes VMD the better “duration” asset for the next 12 months, especially if Medicare utilization trends remain stable.

SGRY’s real issue is not just leverage; it is option value dilution. High debt plus low margin means any reimbursement wobble, wage pressure, or acquisition integration miss gets absorbed by equity holders first, and the company has less flexibility to defend pricing against larger systems. The second-order risk is that competitors with stronger payer relationships can use bundled care and referral capture to pressure outpatient volumes, which would make SGRY’s revenue growth look more cyclical than secular.

The consensus may be too complacent about VMD’s concentration risk, but that is a timing issue, not a thesis breaker. The key catalyst window is the next 2-3 quarters: if reimbursement is stable and management keeps converting growth into cash, the market should rerate VMD as a quality compounder rather than a niche provider. The main reversal trigger is policy, but absent a reimbursement shock, the balance-sheet gap alone should keep the spread in VMD’s favor.

The contrarian point: SGRY’s cheapness is real and may attract value buyers, but it is a classic value trap until leverage comes down or growth reaccelerates beyond low single digits. In contrast, VMD’s multiple is not demanding relative to its growth and balance-sheet profile, so even modest execution beats can drive multiple expansion over the next year.

Key Decisions for Investors

• Long VMD vs short SGRY in a market-neutral pair trade over 6-12 months; thesis is quality-growth plus balance-sheet advantage, with upside from multiple expansion and downside protection if healthcare multiples compress broadly.
• Buy VMD on any 5-8% pullback post-earnings; target a 12-month rerating as growth remains above 15% and cash generation continues to de-risk the story.
• Avoid initiating new long SGRY positions until leverage trends lower or margins inflect; if holding, treat as a trading name and use rallies toward consensus growth expectations to trim exposure.
• For more aggressive portfolios, use call spreads on VMD for the next 2 quarters to express upside from reimbursement stability and continued share gains without taking full equity downside.
• If Medicare policy headlines turn negative, hedge VMD with a short-term put spread rather than rotating into SGRY; the latter likely underperforms on any broad healthcare stress because balance-sheet sensitivity is higher.